Bessemer Group Inc. Has $71.83 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Bessemer Group Inc. decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 923,632 shares of the medical device company's stock after selling 40,276 shares during the quarter. Bessemer Group Inc. owned about 0.24% of DexCom worth $71,832,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in DexCom in the fourth quarter valued at approximately $385,367,000. Congress Asset Management Co. raised its position in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD acquired a new stake in shares of DexCom during the fourth quarter worth about $96,507,000. Jennison Associates LLC lifted its position in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after acquiring an additional 710,858 shares during the period. Finally, ExodusPoint Capital Management LP increased its stake in DexCom by 197.6% in the 4th quarter. ExodusPoint Capital Management LP now owns 466,414 shares of the medical device company's stock valued at $36,273,000 after buying an additional 309,714 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

DexCom stock traded up $0.82 during trading hours on Tuesday, hitting $68.21. The stock had a trading volume of 1,603,490 shares, compared to its average volume of 4,183,518. The company has a market cap of $26.75 billion, a PE ratio of 47.70, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24. The company has a 50-day moving average of $76.49 and a two-hundred day moving average of $76.68. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Mizuho started coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus target price of $99.00.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 over the last three months. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.